Lipocine (LPCN) Operating Income (2012 - 2025)
Lipocine's (LPCN) quarterly Operating Income came in at -$3.4 million in Q3 2025, down 27.77% YoY from -$4.7 million in Q3 2024, and down 39.79% on a QoQ basis from -$2.4 million in Q2 2025.
Lipocine (LPCN) Operating Income (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Operating Income data on file, last reported at -$3.4 million in Q3 2025.
- Quarterly Operating Income fell 27.77% year-over-year to -$3.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$6.3 million (down 19.2% YoY) and the FY2024 annual result came in at -$1.2 million, up 93.56% from the prior year.
- Operating Income eased to -$3.4 million in Q3 2025, from -$2.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $12.8 million in Q4 2021 to a low of -$7.0 million in Q3 2023.
- A 5-year average of -$1.9 million and a median of -$3.0 million in 2021 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income soared 366.24% — and 2025, when it sank 164.86%.
- Tracing LPCN's Operating Income over 5 years: stood at $12.8 million in 2021, then sank by 120.03% to -$2.6 million in 2022, then retreated by 1.27% to -$2.6 million in 2023, then soared by 159.59% to $1.5 million in 2024, then plunged by 317.48% to -$3.4 million in 2025.
- The last three Operating Income figures came in at -$3.4 million (Q3 2025), -$2.4 million (Q2 2025), and -$2.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.36 Mn |
| Jun 30, 2025 | -2.40 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -3.29 Mn |
| Mar 31, 2024 | 3.22 Mn |
| Dec 31, 2023 | -2.59 Mn |
| Sep 30, 2023 | -7.04 Mn |
| Jun 30, 2023 | -3.96 Mn |
| Mar 31, 2023 | -4.34 Mn |
| Dec 31, 2022 | -2.56 Mn |
| Sep 30, 2022 | -2.90 Mn |
| Jun 30, 2022 | -3.53 Mn |
| Mar 31, 2022 | -3.13 Mn |
| Dec 31, 2021 | 12.78 Mn |
| Sep 30, 2021 | -3.53 Mn |
| Jun 30, 2021 | -2.99 Mn |
| Mar 31, 2021 | -3.11 Mn |
| Dec 31, 2020 | -4.80 Mn |